June 16, 2020 / 6:19 AM / 22 days ago

BRIEF-Ryvu Therapeutics Adopts Strategy For 2020-2022

June 16 (Reuters) - Ryvu Therapeutics SA:

* SAID ON MONDAY MANAGEMENT HAS ADOPTED A NEW STRATEGY FOR 2020-2022

* PLANS TO COMPLETE PHASE I CLINICAL DEVELOPMENT OF SEL120 IN ACUTE MYELOID LEUKAEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)

* PLANS TO EXPAND THERAPEUTIC POTENTIAL FOR SEL120 IN SOLID TUMOURS AND LAUNCH NEW PHASE I STUDY IN SELECTED INDICATIONS IN PARALLEL TO ONGOING HEMATO-ONCOLOGY STUDIES

* PLANS TO SUPPORT PHASE II DEVELOPMENT BY MENARINI FOR LEAD PARTNERED CANDIDATE, SEL24/MEN1703 IN AML

* PLANS TO COMPLETE PRECLINICAL PROGRAMS FOR A2A/A2B AND STING CANDIDATES AND ADVANCE AT LEAST ONE PROGRAM INTO PHASE I OF CLINICAL TRIALS

* PLANS TO STRENGTHEN POSITION IN NOVEL TARGET DISCOVERY FOR SYNTHETIC LETHALITY AND IMMUNE-ONCOLOGY AND IN DEVELOPING NOVEL, PROPRIETARY DRUG CANDIDATES

* PLANS TO PARTNER SELECTED EARLY PIPELINE PROGRAMS WITH BIOTECH AND PHARMA COMPANIES PROVIDING SYNERGISTIC COMPETENCES AND RESOURCES, WITH AT LEAST ONE NEW PARTNERING AGREEMENT IN 2020

* IS TARGETING TO RAISE ABOUT 150 MILLION ZLOTYS FROM SHARE ISSUE

Source text for Eikon:

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below